Jump to main content
Jump to site search


Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy

Author affiliations

Abstract

Photodynamic therapy (PDT) combines a photosensitizer (PS) with the physical energy of non-ionizing light to trigger cell death pathways. PDT has potential as a therapeutic modality to be used in alternative or in combination with other conventional cancer treatment protocols (e.g. surgery, chemotherapy and radiotherapy). Still, due to the lack of specificity of the current PSs to target the tumor cells, several studies have exploited their conjugation with targeting moieties. PSs conjugated with antibodies (Abs) or their fragments, able to bind antigens overexpressed in the tumors, have demonstrated potential in PDT of tumors. This review provides an overview of the most recent advances on photoimmunoconjugates (PICs) for cancer PDT, which involve the first and second-generation PSs conjugated to Abs. This is an update of our previous review “Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications”, published in 2015 in Org. Biomol. Chem.

Graphical abstract: Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy

Back to tab navigation

Publication details

The article was received on 20 Nov 2018, accepted on 08 Jan 2019 and first published on 08 Jan 2019


Article type: Review Article
DOI: 10.1039/C8OB02902D
Citation: Org. Biomol. Chem., 2019, Advance Article
  •   Request permissions

    Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy

    S. R. G. Fernandes, R. Fernandes, B. Sarmento, P. M. R. Pereira and J. P. C. Tomé, Org. Biomol. Chem., 2019, Advance Article , DOI: 10.1039/C8OB02902D

Search articles by author

Spotlight

Advertisements